SCYNEXIS公司宣布,已启动其新型药物SCY-770的一期临床研究。该药物作为一种创新的AMPK激活剂,开发用于治疗常染色体显性多囊肾病。
公司预计,针对ADPKD的二期研究将于2026年第四季度开始。此外,一期研究的关键顶线数据有望在2026年第三季度获得。
SCYNEXIS公司宣布,已启动其新型药物SCY-770的一期临床研究。该药物作为一种创新的AMPK激活剂,开发用于治疗常染色体显性多囊肾病。
公司预计,针对ADPKD的二期研究将于2026年第四季度开始。此外,一期研究的关键顶线数据有望在2026年第三季度获得。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.